Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing

Our "Peanut Allergy" Biotech IPO Debuts Today

Aimmune Therapeutics Inc. (Nasdaq: AIMT), the Brisbane, Calif.-based biotech that's developed one of the first true treatments for peanut-allergy sufferers, is scheduled to make its public debut today.

The firm's shares are supposed to start trading today after an initial public offering (IPO) of 8.33 million shares in a price range of $14 a share to $16 a share.

Although we don't often recommend IPO stocks, we made an exception here in a special report we gave you back on July 27. Aimmune is a development-stage biotech, but its lead product is about to enter late-stage clinical trials.

With the stock scheduled to begin trading today, let's take another look at the firm, its lead product - and the market it's looking to serve.

Full Story
  1. kai Tastula | August 9, 2015

    No comments good stories.

Leave a Reply

Your email address will not be published. Required fields are marked *

Some HTML is OK